Gao Fei, Xu Yong-Gang, Yang Xiao-Hong, Ma Rou
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014 Feb;34(2):174-8.
To study the effect of Qinghuang Powder (QHP) combined Chinese herbs for Pi-strengthening and Shen-reinforcing (CHPSSR) on hypoxia-inducible factor 1alpha (HIF-1alpha) in bone marrow mononuclear cells of myelodysplastic syndrome (MDS) patients.
Changes of HIF-1alpha in bone marrow mononuclear cells of MDS patients were detected in 25 MDS patients treated by QHP combined CHPSSR using flow cytometry. Meanwhile, 13 healthy subjects were recruited as the control group. Changes HIF-1alpha levels in various serial bone marrow mononuclear cells were detected.
(1) Among the 25 patients in the treatment group, there were 19 patients effective and 6 patients ineffective, with the total effective rate being 76%. (2) Compared with before treatment, levels of peripheral blood WBC, Hb, PLT, and ANC significantly increased in the treatment group after treatment, showing statistical difference (P < 0.05, P < 0.01). (3) Compared with before treatment, the HIF-1alpha mean fluorescence intensity was enhanced in bone marrow lymphocytes, monocytes, granulocytes, and nucleated red blood cells of the treatment group after treatment (P < 0.05, P < 0.01). Compared with the control group, the HIF-1alpha mean fluorescence intensity was weakened in bone marrow lymphocytes, monocytes, and nucleated red blood cells of the treatment group before treatment; while it was obviously enhanced in granulocytes (P < 0.01). But after treatment the HIF-1alpha mean fluorescence intensity increased more in the granulocytes of the treatment group than in those of the control group (P < 0.01), but there was no statistical difference in bone marrow lymphocytes, monocytes, or nucleated red blood cells.
QHP combined CHPSSR could improve HIF-1alpha levels in bone marrow lymphocytes, monocytes, granulocytes, and nucleated red blood cells of MDS patients, thus improving Hb levels of MDS patients, and improving their anemia and correlated symptoms.
研究清黄散（QHP）联合健脾补肾中药（CHPSSR）对骨髓增生异常综合征（MDS）患者骨髓单个核细胞中缺氧诱导因子1α（HIF-1α）的影响。
采用流式细胞术检测25例接受QHP联合CHPSSR治疗的MDS患者骨髓单个核细胞中HIF-1α的变化。同时，招募13名健康受试者作为对照组，检测不同系列骨髓单个核细胞中HIF-1α水平的变化。
（1）治疗组25例患者中，有效19例，无效6例，总有效率为76%。（2）治疗组治疗后外周血白细胞、血红蛋白、血小板和中性粒细胞绝对值水平较治疗前显著升高，差异有统计学意义（P<0.05，P<0.01）。（3）治疗组治疗后骨髓淋巴细胞、单核细胞、粒细胞和有核红细胞中HIF-1α平均荧光强度较治疗前增强（P<0.05，P<0.01）。治疗组治疗前骨髓淋巴细胞、单核细胞和有核红细胞中HIF-1α平均荧光强度较对照组减弱；而粒细胞中则明显增强（P<0.01）。但治疗后治疗组粒细胞中HIF-1α平均荧光强度升高幅度大于对照组（P<0.01），而骨髓淋巴细胞、单核细胞或有核红细胞中无统计学差异。
QHP联合CHPSSR可提高MDS患者骨髓淋巴细胞、单核细胞、粒细胞和有核红细胞中HIF-1α水平，从而提高MDS患者血红蛋白水平，改善其贫血及相关症状。
